Drug DevelopmentVK2735, a GLP-1/GIP dual agonist, is considered incrementally better than tirzepatide, offering improved potency and pharmacokinetics.
Financial StabilityViking Therapeutics has a strong cash position of $852M, which is expected to be sufficient to fund its Phase 3 study for injectable VK2735 and the Phase 2 oral study.
Market PotentialThe obesity market is large enough to accommodate VK2735, with expectations that it will rise to multi-blockbuster status due to its improvements over existing therapies.